Key Performance Drivers

The growth was not uniform across all factors, but rather driven by specific levers:

• Price Increases: Contributed approximately 5.4% to the growth. Remains the primary engine of total market value expansion
• New Product Introductions (NPIs): Added 2.8%, showing a shift toward innovation-led revenue.
• Volume Growth: Remained modest at 1.8%, indicating that while people are paying more for newer or adjusted medicines, the actual quantity of units sold is growing slowly.

Therapy & Segment Highlights 

• Anti-Diabetic & GLP-1 Agonists: Recorded exponential, outsized growth lines. The injection and solid formulation spaces expanded dramatically following the introduction of domestic generic Semaglutide and Tirzepatide, causing the overall GLP-1 market to more than triple in active value turnover.
• Cardiac / Cardiovascular: Maintained its status as the single largest base value contributor across the entire IPM index, growing steadily at an estimated 11.5% YoY.
• Vaccines & Specialty Biologics: Emerged as the absolute fastest-growing clinical category, logging a stellar value spike of 22.7% driven by aggressive pediatric healthcare rollouts and biosimilar absorption.
• Gastrointestinal & Anti-Infectives: Maintained high baseline prescription numbers but experienced slower relative value expansion, averaging between 4.0% and 4.3% due to stricter antimicrobial stewardship across Tier-1 and Tier-2 medical facilities.